Stocks › JAZZ
Jazz Pharmaceuticals plc
JAZZ·Nasdaq·USD
$231.39
-4.65 (-1.97%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
JAZZ
Jazz Pharmaceuticals plc · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
JAZZS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of JAZZ by members of U.S. Congress · 16 on record
Whale Activity
Position changes in JAZZ reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| ARGENT CAPITAL MANAGEMENT LLC | 193.2K | $44.7M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by JAZZ insiders, by quarter · Form 4
Recent Insider Transactions
2,006 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| COZADD BRUCE CDirector · Director | Sale | −6,000 | $230.33 | $1.4M | Oct 1, 2026 | Form 4 ↗ |
| Patil Neena MEVP & Chief Legal Officer | Sale | −1,200 | $240.94 | $289K | Sep 10, 2026 | Form 4 ↗ |
| GALA RENEE DPresident & CEO | Sale | −2,000 | $243.03 | $486K | Sep 8, 2026 | Form 4 ↗ |
| COZADD BRUCE CDirector · Director | Sale | −6,000 | $250.13 | $1.5M | Sep 1, 2026 | Form 4 ↗ |
| Iannone RobertEVP, Global Head of R&D & CMO | Sale | −9,259 | $251.95 | $2.3M | Aug 27, 2026 | Form 4 ↗ |
| Iannone RobertEVP, Global Head of R&D & CMO | Sale | −300 | $252.76 | $76K | Aug 27, 2026 | Form 4 ↗ |
| Iannone RobertEVP, Global Head of R&D & CMO | Sale | −19.6K | $250.60 | $4.9M | Aug 27, 2026 | Form 4 ↗ |
| Iannone RobertEVP, Global Head of R&D & CMO | Sale | −18.2K | $247.86 | $4.5M | Aug 27, 2026 | Form 4 ↗ |
| Iannone RobertEVP, Global Head of R&D & CMO | Sale | −18.1K | $250.02 | $4.5M | Aug 27, 2026 | Form 4 ↗ |
| Iannone RobertEVP, Global Head of R&D & CMO | Sale | −11.4K | $248.67 | $2.8M | Aug 27, 2026 | Form 4 ↗ |
| COZADD BRUCE CDirector · Director | Sale | −6,000 | $252.98 | $1.5M | Aug 3, 2026 | Form 4 ↗ |
| COZADD BRUCE CDirector · Director | Sale | −6,000 | $240.47 | $1.4M | Jul 1, 2026 | Form 4 ↗ |
| Smith Mark DouglasDirector | Sale | −1,157 | $230.55 | $267K | Jun 15, 2026 | Form 4 ↗ |
| Patil Neena MEVP & Chief Legal Officer | Sale | −1,200 | $231.83 | $278K | Jun 10, 2026 | Form 4 ↗ |
| GALA RENEE DPresident & CEO | Gift | −600 | $0.00 | $0 | Jun 3, 2026 | Form 4 ↗ |
| COZADD BRUCE CDirector | Sale | −6,000 | $235.12 | $1.4M | Jun 1, 2026 | Form 4 ↗ |
| Pearce SamanthaEVP, Chief Commercial Officer | Sale | −6,907 | $235.41 | $1.6M | May 28, 2026 | Form 4 ↗ |
| Pearce SamanthaEVP, Chief Commercial Officer | Option exercise | +6,907 | $109.45 | $756K | May 28, 2026 | Form 4 ↗ |
| Patil Neena MEVP & Chief Legal Officer | Sale | −1,192 | $236.97 | $282K | May 28, 2026 | Form 4 ↗ |
| Mulligan SeamusDirector | Option exercise | +3,415 | $138.08 | $472K | May 28, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding JAZZ · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $456.0M | 0.02% | Jun 30, 2026 |
| FULLERTHALER BEHAVIORAL SMALL CAP EQUITY Capitol Series Trust | 1.6M | $376.3M | 2.97% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.4M | $329.3M | 0.17% | Jun 30, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 865.9K | $208.7M | 0.31% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 719.2K | $173.3M | 0.18% | Jun 30, 2026 |
| VictoryShares Free Cash Flow ETF Victory Portfolios II | 469.9K | $113.2M | 1.46% | Jun 30, 2026 |
| PIMCO RAE US Small Fund PIMCO Equity Series | 388.3K | $73.4M | 2.34% | Mar 31, 2026 |
| Dimensional U.S. Small Cap ETF Dimensional ETF Trust | 168.6K | $42.6M | 0.28% | Jul 31, 2026 |
| VANGUARD WINDSOR FUND VANGUARD WINDSOR FUNDS | 201.6K | $40.9M | 0.17% | Apr 30, 2026 |
| iShares U.S. Pharmaceuticals ETF iShares Trust | 163.0K | $39.3M | 3.45% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list JAZZ's shares (CUSIP G50871105), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming jazz pharmaceuticals as client
- TARPLIN, DOWNS & YOUNG, LLCJAZZ PHARMACEUTICALS INC. · 2026 Q2 · HCR$80K
Filing ↗ - JAZZ PHARMACEUTICALS, INC.JAZZ PHARMACEUTICALS, INC. · 2026 Q2 · PHA$490K
Filing ↗ - AVENUE SOLUTIONSJAZZ PHARMACEUTICALS, INC. · 2026 Q2 · HCR, MMM$50K
Filing ↗ - THE NICKLES GROUP, LLCJAZZ PHARMACEUTICALS, INC. · 2026 Q2 · MMM, TRD$50K
Filing ↗ - TIBER CREEK GROUPJAZZ PHARMACEUTICALS · 2026 Q2 · HCR, MED, BUD$50K
Filing ↗
Government Contracts
Federal awards to jazz pharmaceuticals · USAspending
$337KAwarded · 2 contracts on record
U.S. Patents
Recent USPTO applications naming Jazz Pharmaceuticals plc
No USPTO patent applications found for Jazz Pharmaceuticals plc.
Annual Financials
From JAZZ's 10-K filings · XBRL
No annual XBRL figures on record for JAZZ. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in JAZZ's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationSep 23, 2026
EDGAR ↗ - 8-K · Items 7.01Reg FD disclosureSep 15, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 3.02, 8.01, 9.01Material agreement · Direct financial obligation · Unregistered sale of equityAug 31, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsAug 25, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementAug 10, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureAug 10, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 3, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJul 24, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeMay 29, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
About Jazz Pharmaceuticals plc
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersDUBLIN
IncorporatedL2
SEC CIK0001232524 ↗
Former namesJAZZ PHARMACEUTICALS INC